B-North Unquoted SME lender with unique proposition

Hardman & Co

B-North is raising capital ahead of getting its banking licence (due spring 2020). It will then attack the huge, profitable and poorly-served SME lending market. B-North combines i) state-of-the-art technology (built from scratch to address customers’ needs), ii) offering the £20bn+ p.a. commercial broker market an unparalleled service and an innovative remuneration model, and iii) experienced bankers based in empowered regional hubs. It should be more efficient than its peers, and will use technology to be close to customers. The financial model assumes a market share of just 2.5% in 2027. Delivery of this sees a highly profitable, and valuable, business, in our view.

  • Near-term capital raises:  B-North is currently raising up to £2m through private subscriptions through the Growthfunders and Crowdcube platforms. It anticipates raising a further £20m (through Berenberg), conditional on the approval of the banking licence due in March 2020. Further raises are planned.
  • “Reality-check”:  We have reviewed the company assumptions and believe them to be ambitious but credible. We have considered the absolute performance and the level of lending that peers have achieved. Importantly, B-North has multiple options to address any volume shortfall – most at a modest cost.
  • Valuation:  Given the growth profile of the company and associated uncertainties, any valuation must be treated with extreme caution. We provide a range of approaches (p46-48) that, on average, indicate B-North’s value in 2027 could be treble the amount of equity raised. We also provide a range of sensitivities.
  • Risks:  Credit risk is key for any bank. B-North will establish independent credit functions, and its technology will bring it close to customers interfacing directly with its management information. It has multiple options to address any loan growth shortfall. The economic cycle is important. The model is yet to be tested.
  • Investment summary:  B-North is still at the pre-revenue stage. Its model should be low-cost and deliver a superior service to customers and intermediaries. It has a conservative credit culture and uses state-of-the-art technology, written from scratch, to originate, service and manage its business. Funding will be via the deep best-buy retail deposit comparison sites. The potential market is huge, profitable and under-served, and major incumbents have selectively become uncompetitive.

DOWNLOAD THE FULL REPORT

Share on:

Latest Company News

UK skills shortage puts infrastructure delivery under pressure

The UK's infrastructure pipeline is increasing demand for skilled workers, making recruitment, training and workforce technology increasingly important to project delivery.

Meridian takes Expanse Studios to global gaming expo

Meridian’s Expanse Studios heads to G2E Las Vegas with nearly 100 casino titles, 1,800-plus casino brands and regulatory coverage across more than 15 markets.

Personal Group praised by Fund Manager for income growth and market share gains

Premier Miton’s Gervais Williams discusses Personal Group Holdings’ 22% rise in adjusted EBITDA, record insurance sales, improving market share and prospective dividend yield of around 6%.

Cizzle Bio pushes blood test into lung cancer screening

Cizzle Bio is developing a blood test designed to add biomarker information to existing lung cancer screening.

European stocks rise as falling oil prices ease market pressure

European shares rose as lower oil prices eased pressure on markets, with investors now focused on September business activity data for clues about economic growth and interest rates.

The Biotech Growth Trust plc – Why Biotech’s Recovery Could Still Have Further to Run (video)

Biotech valuations have rebounded, pharmaceutical M&A has accelerated and regulatory uncertainty has begun to ease — but Josh Golomb of The Biotech Growth Trust believes the more important story is that innovation never stopped.

    Search